Thousands of Blood-Pressure Pills Recalled Over Reduced Effectiveness

Macleods Pharmaceuticals initiated a nationwide recall of a combination blood-pressure tablet that the FDA classified as Class II on October 26, according to FDA data reported on Wednesday.

The recall covers 3,744 bottles of olmesartan medoxomil, amlodipine and hydrochlorothiazide combination tablets, used to treat hypertension, after the olmesartan component failed dissolution specifications in two lots.

Affected lots include 30-count bottles, Lot 12251163A, NDC 33342-246-07, with expiration May 31, 2027, accounting for 3,528 bottles in that configuration.

The FDA defines a Class II recall as one where exposure may cause temporary or medically reversible consequences, with serious harm considered remote. The concern here is reduced effectiveness, not contamination, according to the reporting.

Patients should not stop taking blood-pressure medication without talking to a doctor or pharmacist, and should check lot numbers with their pharmacy if they take this combination tablet.